---
title: "Ultragenyx制药 (RARE.US) — 财务报表"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/RARE.US/norm.md"
symbol: "RARE.US"
name: "Ultragenyx制药"
parent: "https://longbridge.com/zh-CN/quote/RARE.US.md"
datetime: "2026-05-21T03:24:37.880Z"
locales:
  - [en](https://longbridge.com/en/quote/RARE.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RARE.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RARE.US/norm.md)
---

# Ultragenyx制药 (RARE.US) — 财务报表

## 利润表 (USD)

| 指标 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| 每股收益 | -1.84 | -1.29 | -1.81 | -1.17 | -1.57 |
| ROE | 468.35% | 1451.77% | -899.56% | -311.17% | -302.57% |
| 营业收入 | 136.00M | 207.28M | 159.93M | 166.50M | 139.00M |
| 净利润 | -185.00M | -128.56M | -180.41M | -114.95M | -151.00M |
| 营业利润 | -139.00M | -113.28M | -170.89M | -107.89M | -143.00M |
| 毛利率 | -27.21% | -12.23% | -52.69% | -12.76% | -25.18% |
| 净利率 | -136.03% | -62.02% | -112.81% | -69.04% | -108.63% |
| 利润含金量 | - | - | - | - | - |

## 资产负债表 (USD)

| 指标 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| 资产与负债 | 1.30B | 1.53B | 1.19B | 1.31B | 1.31B |
| 权益乘数 | -5.66 | -20.99 | 73.67 | 8.25 | 8.67 |
| 每股净资产 | -2.41 | -0.8299 | 0.0951 | 1.57 | 1.54 |
| 资产周转率 | 0.5138 | 0.4435 | 0.4618 | 0.4169 | 0.4507 |
| 现金及短投 | 413.00M | 680.00M | 425.25M | 487.58M | 494.44M |
| 存货与应收 | 55.00M | 52.00M | 52.20M | 46.50M | 46.03M |
| 长期投资 | 239.00M | 267.00M | 249.96M | 255.76M | 260.91M |
| 净债务 | 666.00M | 515.00M | 415.80M | 343.87M | 326.69M |

## 现金流量表 (USD)

| 指标 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| 经营现金流 | -197.00M | -99.83M | -91.42M | -108.27M | -166.00M |
| 投资现金流 | -49.00M | -72.25M | 117.18M | 71.17M | 120.00M |
| 融资现金流 | - | 394.19M | 2000.00 | 83.65M | - |
| 自由现金流 | -77.88M | -38.04M | -3.50M | -56.33M | -114.28M |
| 现金流充裕率 | -19700.00% | -10642.75% | -7153.60% | -4401.34% | -16600.00% |
| 举债与偿债 | - | - | - | - | - |
| 资本支出 | -1.00M | -938000.00 | -1.28M | -2.46M | -1.00M |